Jianmin Pharmaceutical Group Co.,Ltd.

SHSE:600976 Voorraadrapport

Marktkapitalisatie: CN¥6.7b

Jianmin Pharmaceutical GroupLtd Toekomstige groei

Future criteriumcontroles 5/6

Jianmin Pharmaceutical GroupLtd is forecast to grow earnings and revenue by 26.8% and 14.4% per annum respectively. EPS is expected to grow by 26.7% per annum. Return on equity is forecast to be 21.2% in 3 years.

Belangrijke informatie

26.8%

Groei van de winst

26.7%

Groei van de winst per aandeel

Pharmaceuticals winstgroei19.3%
Inkomstengroei14.4%
Toekomstig rendement op eigen vermogen21.2%
Dekking van analisten

Low

Laatst bijgewerkt09 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Sep 25
If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

Aug 25
Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

Jul 12
The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30
We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21
We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26
We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Winst- en omzetgroeiprognoses

SHSE:600976 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20265,708851N/A6872
12/31/20255,116707N/A3592
12/31/20244,590573N/A3632
9/30/20243,97742891206N/A
6/30/20244,061508156245N/A
3/31/20244,170521214284N/A
12/31/20234,213521204268N/A
9/30/20233,948508221287N/A
6/30/20233,965472131212N/A
3/31/20233,736419196270N/A
12/31/20223,641408148216N/A
9/30/20223,50336396152N/A
6/30/20223,344326203254N/A
3/31/20223,3763243788N/A
12/31/20213,299305192248N/A
9/30/20213,456279197253N/A
6/30/20213,221258130175N/A
3/31/20212,857199127175N/A
1/1/20212,45614880126N/A
9/30/20202,01314494149N/A
6/30/20202,154931483N/A
3/31/20202,164831181N/A
1/1/20202,23991574N/A
9/30/20192,40282-3235N/A
6/30/20192,19980-1241N/A
3/31/20192,183792773N/A
1/1/20192,161812164N/A
9/30/20182,188915192N/A
6/30/20182,311100N/A130N/A
3/31/20182,625102N/A93N/A
12/31/20172,71291N/A35N/A
9/30/20172,74881N/A72N/A
6/30/20172,67771N/A54N/A
3/31/20172,31559N/A41N/A
12/31/20162,36465N/A114N/A
9/30/20162,49569N/A87N/A
6/30/20162,43080N/A21N/A
3/31/20162,44983N/A2N/A
12/31/20152,28186N/A48N/A
9/30/20151,95386N/A49N/A
6/30/20151,860102N/A130N/A
3/31/20151,748114N/A107N/A
12/31/20141,753116N/A103N/A
9/30/20141,685118N/A56N/A
6/30/20141,716108N/A56N/A
3/31/20141,86798N/A89N/A
12/31/20131,99296N/A45N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 600976's forecast earnings growth (26.8% per year) is above the savings rate (2.9%).

Winst versus markt: 600976's earnings (26.8% per year) are forecast to grow faster than the CN market (25.8% per year).

Hoge groeiwinsten: 600976's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: 600976's revenue (14.4% per year) is forecast to grow faster than the CN market (14% per year).

Hoge groei-inkomsten: 600976's revenue (14.4% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: 600976's Return on Equity is forecast to be high in 3 years time (21.2%)


Ontdek groeibedrijven